indicated that the TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and pentose phosphate pathway metabolism, which might be an underlying therapeutic target for cancers with PTEN loss or PI3K/AKT activation (30). This evidence concerns the gene AKT1 and cancer.